Jane Street Group, LLC Fate Therapeutics Inc Call Options Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	SELL	$29.67 - $60.28 $1.64 Million - $3.33 Million	-55,200 Reduced 72.82%	20,600 $799,000
Q4 2021 Feb 15, 2022	BUY	$47.84 - $64.34 $3.29 Million - $4.42 Million	68,700 Added 967.61%	75,800 $4.44 Million
Q3 2021 Nov 16, 2021	BUY	$59.27 - $95.73 $53,343 - $86,157	900 Added 14.52%	7,100 $421,000
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $390,050 - $536,616	-5,800 Reduced 48.33%	6,200 $538,000
Q1 2021 May 18, 2021	BUY	$72.16 - $117.4 $627,792 - $1.02 Million	8,700 Added 263.64%	12,000 $989,000
Q4 2020 Feb 17, 2021	SELL	$38.09 - $100.95 $213,304 - $565,320	-5,600 Reduced 62.92%	3,300 $300,000
Q2 2020 Aug 17, 2020	BUY	$20.21 - $35.23 $179,869 - $313,547	8,900 New	8,900 $305,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.